SCIEX Upgrades BioPhase 8800 for mRNA Quality Control and Lab Automation

MARLBOROUGH, Mass. – September 28, 2026 – As the pharmaceutical industry accelerates its shift toward advanced modalities like mRNA vaccines, CRISPR guide RNAs, and tailored gene therapies, the analytical instrumentation required to validate these complex molecules is undergoing a silent but critical evolution. SCIEX, an operating company within Danaher Corporation’s life sciences portfolio, announced today a suite of enhancements to its BioPhase 8800 multi-capillary electrophoresis system. The updates, which include a new compliance-ready software architecture, an open application programming interface, and a high-resolution oligonucleotide analysis kit, reflect a broader industry mandate: bridging the gap between cutting-edge molecular biology and fully automated, tightly regulated quality control pipelines.

Unlocking the Bottleneck: Multi-Capillary Electrophoresis in mRNA Quality Control

The rapid commercialization of mRNA therapeutics has exposed significant bottlenecks in downstream analytical characterization. Unlike traditional small-molecule drugs or even monoclonal antibodies, mRNA molecules are massive, highly engineered transcripts that require precise structural validation before batch release. One of the most critical quality attributes of therapeutic in vitro transcribed (IVT) mRNA is the 3-prime polyadenosine, or poly(A), tail.

Typically engineered to be between 100 and 150 nucleotides in length, the poly(A) tail dictates the stability and translational efficacy of the transcript by binding to proteins that facilitate the cellular translation complex. Tails that fall short of this threshold trigger rapid deadenylation and destruction by the cellular exosome, rendering the therapeutic inert. However, accurately measuring the length and polydispersity of these tails presents a formidable analytical challenge.

Traditional methods often fall short when deployed at an industrial scale. Ion-pair reversed-phase liquid chromatography coupled with mass spectrometry (IP-RP-LC-MS) provides atomic-level mass confirmation but suffers from extreme charge-state distribution broadening and spectral congestion when analyzing intact molecules or fragments exceeding 100 nucleotides. Next-generation sequencing techniques, while capable of resolving individual molecules, lack the validated Good Manufacturing Practice (GMP) status required for commercial batch release and suffer from complex bioinformatic overhead.

To address this, the newly released Oligo 200 nt Purity and Integrity kit leverages capillary gel electrophoresis to achieve single-nucleotide resolution up to 141 nucleotides. In a typical workflow, the mRNA is annealed to a complementary DNA probe and selectively cleaved using Ribonuclease H, freeing the intact poly(A) tail. The BioPhase 8800 then separates these fragments across an eight-capillary array utilizing circulating liquid coolant. This thermal management is critical; unlike competing forced-air systems, the liquid cooling maintains tight temperature control, preventing the Joule heating that typically distorts migration velocity and peak shape in high-resolution oligonucleotide separations. By enabling single-nucleotide separation in a high-throughput format, analytical development groups can cut batch-release timelines significantly without sacrificing the granular data required by regulatory bodies.

The Connected QC Lab: API-Driven Automation and Regulatory Compliance

Beyond the chemistry, the modern biopharmaceutical laboratory is facing intense pressure to reduce manual touchpoints. High-throughput process analytical labs analyze tens of thousands of samples annually, and the traditional model of stand-alone instruments functioning as isolated data silos is no longer sustainable. The push toward "lights-out" autonomous laboratory workflows requires instruments that can communicate seamlessly with overarching orchestration software.

The introduction of the BioPhase Instrument API marks a strategic pivot toward open ecosystem connectivity. By exposing operational statuses, remote sequence execution capabilities, and automated data exfiltration pathways, the platform aligns with modern Standardization in Lab Automation (SiLA 2) principles. Automation schedulers can now programmatically construct sample sequence tables, initiate runs, and monitor real-time telemetry without physical user intervention. In practice, this allows robotic liquid handlers, such as the Beckman Coulter Biomek workstations, to automate the complex RNase H digestion and plate setup, hand the microplates directly to the multi-capillary system via robotic grippers, and initiate the analytical run entirely via API calls.

However, automation without compliance is a non-starter in the heavily regulated pharmaceutical sector. For late-phase clinical manufacturing and commercial release, analytical software must adhere strictly to FDA 21 CFR Part 11 and EU GMP Annex 11 guidelines. BioPhase Software 1.6 addresses this by embedding robust data integrity architecture directly into the operating system.

The updated software introduces granular role-based access control, cryptographic electronic signatures with dual-approval loops, and system-generated, unalterable audit trails. Every operator action, parameter adjustment, and integration modification is time-stamped and decoupled from administrative privileges, ensuring that history logs cannot be overwritten. By adhering to ALCOA+ principles—ensuring data is attributable, legible, contemporaneous, original, and accurate—the software provides the rigorous governance required for enterprise chromatography data systems, preventing data transfer bottlenecks between research and development and quality control environments.

Strategic Positioning within the Life Sciences Ecosystem

From a macroeconomic perspective, these updates fortify Danaher’s position in the highly competitive life sciences sector. By integrating the multi-capillary electrophoresis platform more deeply into automated, compliant workflows, the corporation provides an end-to-end tooling ecosystem for mRNA and cell therapy pipelines, linking upstream plasmid DNA suppliers and downstream data management platforms.

This strategic enhancement also serves as a defensive moat against competitors like Agilent and Waters, whose platforms dominate different niches of the analytical landscape. While Agilent prioritizes extreme parallelization for library screening and Waters focuses on high-end LC-MS characterization, the upgraded BioPhase system carves out a vital space in routine, high-throughput commercial quality control where reproducibility, compliance, and speed are paramount.

"Our customers are looking to accelerate development timelines while maintaining confidence in data quality, compliance, and scalability," explained Jose Castro-Perez, Vice President of Product Management at SCIEX. "These new BioPhase 8800 system capabilities strengthen regulated workflow support, enable deeper automation integration, and expand analytical coverage for emerging oligonucleotide-based therapeutics, helping laboratories move faster from development to decision."

Ultimately, the evolution of analytical instrumentation reflects the maturation of the advanced therapeutics market itself. As the scientific complexities of mRNA and gene therapies become standardized, the tools used to measure them must transition from bespoke research instruments into robust, automated engines of commercial manufacturing. With these latest enhancements, the industry takes another step toward a future where precise molecular validation is seamlessly woven into the fabric of autonomous drug production.